They show that the use of FTO inhibitor (Meclofenamic acid MA) [91] to target glioblastoma stem cells (GSCs), results in suppressing GSC-induced tumorigenesis as well as increasing the lifespan of GSC-engrafted mice [16]. This evidence concerns the gene FTO and glioblastoma.